Israel Englander Tg Therapeutics, Inc. Transaction History

Millennium Management LLC

$207 Billion
Q2 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 1,457,908 shares of TGTX stock, worth $35.9 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,457,908

Previous 3,484,046 58.15%

Holding current value

$35.9 Million

Previous $53 Million 51.06%

% of portfolio

0.01%

Previous 0.02%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$13.32 - $19.19 $27 Million - $38.9 Million	-2,026,138 Reduced 58.15%	1,457,908 $25.9 Million
Q1 2024 May 15, 2024	BUY	$13.02 - $21.3 $7.23 Million - $11.8 Million	555,258 Added 18.96%	3,484,046 $53 Million
Q4 2023 Feb 14, 2024	BUY	$6.68 - $18.81 $14 Million - $39.4 Million	2,093,658 Added 250.7%	2,928,788 $50 Million
Q2 2023 Aug 14, 2023	SELL	$15.48 - $35.0 $27.7 Million - $62.7 Million	-1,791,443 Reduced 68.2%	835,130 $20.7 Million
Q1 2023 May 15, 2023	SELL	$10.23 - $19.34 $36.5 Million - $69 Million	-3,566,599 Reduced 57.59%	2,626,573 $39.5 Million
Q4 2022 Feb 14, 2023	BUY	$5.01 - $11.83 $11.2 Million - $26.4 Million	2,230,975 Added 56.31%	6,193,172 $73.3 Million
Q3 2022 Nov 14, 2022	SELL	$4.57 - $8.4 $4.55 Million - $8.37 Million	-996,355 Reduced 20.09%	3,962,197 $23.5 Million
Q2 2022 Aug 15, 2022	BUY	$3.74 - $10.66 $10.4 Million - $29.7 Million	2,781,903 Added 127.81%	4,958,552 $21.1 Million
Q1 2022 May 16, 2022	BUY	$7.81 - $20.45 $12.8 Million - $33.5 Million	1,640,258 Added 305.8%	2,176,649 $20.7 Million
Q4 2021 Feb 14, 2022	BUY	$15.2 - $35.51 $7.88 Million - $18.4 Million	518,633 Added 2920.56%	536,391 $10.2 Million
Q3 2021 Nov 15, 2021	SELL	$21.78 - $40.45 $2.21 Million - $4.1 Million	-101,456 Reduced 85.1%	17,758 $591,000
Q2 2021 Aug 16, 2021	SELL	$32.5 - $48.96 $6.41 Million - $9.66 Million	-197,257 Reduced 62.33%	119,214 $4.62 Million
Q1 2021 May 17, 2021	SELL	$41.61 - $54.3 $9.49 Million - $12.4 Million	-228,105 Reduced 41.89%	316,471 $15.3 Million
Q4 2020 Feb 16, 2021	SELL	$25.27 - $54.9 $1.33 Million - $2.9 Million	-52,814 Reduced 8.84%	544,576 $28.3 Million
Q3 2020 Nov 16, 2020	SELL	$18.49 - $27.24 $14.6 Million - $21.5 Million	-789,069 Reduced 56.91%	597,390 $16 Million
Q2 2020 Aug 14, 2020	BUY	$8.9 - $21.84 $2.69 Million - $6.59 Million	301,818 Added 27.83%	1,386,459 $27 Million
Q1 2020 May 14, 2020	SELL	$7.14 - $15.99 $14.4 Million - $32.2 Million	-2,012,402 Reduced 64.98%	1,084,641 $10.7 Million
Q4 2019 Feb 14, 2020	SELL	$5.1 - $11.2 $22.6 Million - $49.6 Million	-4,424,867 Reduced 58.83%	3,097,043 $34.4 Million
Q3 2019 Nov 14, 2019	BUY	$5.38 - $8.99 $11.6 Million - $19.4 Million	2,162,051 Added 40.34%	7,521,910 $42.2 Million
Q2 2019 Aug 15, 2019	BUY	$6.27 - $8.65 $32.9 Million - $45.3 Million	5,241,560 Added 4430.77%	5,359,859 $46.4 Million
Q2 2019 Aug 14, 2019	SELL	$6.27 - $8.65 $30 Million - $41.4 Million	-4,787,487 Reduced 97.59%	118,299 $8.72 Million
Q1 2019 May 14, 2019	BUY	$4.02 - $8.04 $19.2 Million - $38.5 Million	4,786,175 Added 4001.45%	4,905,786 $39.4 Million
Q4 2018 Feb 14, 2019	SELL	$3.44 - $5.76 $556,261 - $931,415	-161,704 Reduced 57.48%	119,611 $490,000
Q3 2018 Nov 14, 2018	SELL	$5.15 - $14.0 $1.26 Million - $3.42 Million	-244,237 Reduced 46.47%	281,315 $1.58 Million
Q2 2018 Aug 14, 2018	BUY	$12.5 - $15.0 $1.69 Million - $2.03 Million	135,562 Added 34.76%	525,552 $6.91 Million
Q1 2018 May 15, 2018	BUY	$8.7 - $16.8 $3.39 Million - $6.55 Million	389,990 New	389,990 $5.54 Million
Q4 2017 Feb 14, 2018	SELL	$7.35 - $12.3 $973,147 - $1.63 Million	-132,401 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$10.0 - $12.7 $1.32 Million - $1.68 Million	132,401	132,401 $1.57 Million

Others Institutions Holding TGTX

# of Institutions

287

Shares Held

91.8M

Call Options Held

1.9M

Put Options Held

1.45M

View Full List

About TG THERAPEUTICS, INC.

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $3.58B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

More about TGTX

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account